Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703745 | 0.88 | MMP2 (0.55) | PSIP1 | |
| SCHEMBL2705059 | 0.83 | LARS1 (0.51) | PSIP1TP53ALDH1A1MAPTTHRB | |
| SCHEMBL8909374 | 0.83 | PSIP1 (0.56) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL8910619 | 0.83 | PSIP1 (0.56) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL27596821 | 0.83 | PSIP1 (0.56) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL9426107 | 0.83 | PSIP1 (0.56) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL1972951 | 0.83 | PSIP1 (0.56) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL7724605 | 0.83 | PSIP1 (0.56) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL15214393 | 0.82 | PSIP1 (0.50) | PSIP1HSD11B1POLBTP53ALDH1A1 | |
| SCHEMBL2444476 | 0.81 | PSIP1 (0.59) | PSIP1HSD11B1POLBTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113707933-A | Preparation method of solid electrolyte nano dispersion liquid of lithium ion battery and solid electrolyte nano dispersion liquid | 北京卫蓝新能源科技有限公司 | 2021-11-26 | — | — | CN | claimed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | ORION CORP (FI) | 2024-09-19 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | ORION CORPORATION (FI) | 2024-07-09 | — | — | US | disclosed |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | FERRIS STATE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-3350165-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-5266577-A | Method of treating congestive heart failure using carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY LTD. (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5198448-A | Cardiovascular disorders | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| EP-0480986-A1 | 6-(HYDRONAPHTYL-1-ETHYL)-4-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES AND THE CORRESPONDING HYDROXY ACIDS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-04-22 | — | — | EP | disclosed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | disclosed |
| WO-1991000280-A1 | 6-(HYDRONAPHTYL-1-ETHYL)-4-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES AND THE CORRESPONDING HYDROXY ACIDS | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1991-01-10 | — | — | WO | disclosed |
| EP-0367393-A2 | New heterocyclic compounds, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4420433-A | REACTION WITH SILICON TETRACHLORIDE OR TITANIUM TETRACHLORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1983-12-13 | — | — | US | disclosed |
| EP-0071065-A1 | Process for the preparation of fluorine-substituted carboxylic-acid chlorides and aldehydes | BAYER AG (DE) | 1983-02-09 | — | — | EP | disclosed |
| US-4166866-A | Immunosuppressive method with dithiocarbamates | THE CALIFORNIA POLYTECHNIC STATE UNIVERSITY FOUNDATION (US) | 1979-09-04 | — | — | US | disclosed |
| US-4130578-A | Immunosuppressive dithiocarbanilates | THE UPJOHN COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | PIK3CA, PIK3CD, PIK3CB | PSIP1 3815/4885HSD11B1 1906/4885POLB 2432/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | PSIP1 2086/4885HSD11B1 62/4885POLB 3155/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | PSIP1 2126/4885HSD11B1 853/4885POLB 4018/4885 |
| US-12030871-B2 | Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitors | CYP11B1, CYP11B2, CYP4A11 | PSIP1 2752/4885HSD11B1 16/4885POLB 1548/4885 |
| US-20240308989-A1 | PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS | CYP11B1, CYP11B2, CYP4A11 | PSIP1 2420/4885HSD11B1 24/4885POLB 1797/4885 |
| US-11814388-B1 | Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers | AURKA, AURKC, AURKB | PSIP1 1200/4885HSD11B1 2577/4885POLB 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.